{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T22:36:59Z","timestamp":1789511819571,"version":"build-2803163510"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s00210-026-05542-z","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T03:31:26Z","timestamp":1780975886000},"page":"18333-18351","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cardio- and reno-protective effects of candesartan compared to lisinopril in a rat model of cardiorenal syndrome type 4: implication of oxidative stress and inflammation"],"prefix":"10.1007","volume":"399","author":[{"given":"Amany M. Z.","family":"Eldesouky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed M. A.","family":"Shehata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim A.","family":"Awwad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4173-4399","authenticated-orcid":false,"given":"Rasha M. S. M.","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"issue":"6","key":"5542_CR1","doi-asserted-by":"publisher","first-page":"F639","DOI":"10.1152\/ajprenal.00398.2021","volume":"322","author":"RJ Adam","year":"2022","unstructured":"Adam RJ, Williams AC, Kriegel AJ (2022) Comparison of the surgical resection and infarct 5\/6 nephrectomy rat models of chronic kidney disease. Am J Physiol Renal Physiol 322(6):F639\u2013F654","journal-title":"Am J Physiol Renal Physiol"},{"issue":"12","key":"5542_CR2","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1158\/1535-7163.MCT-22-0323","volume":"21","author":"RP Agashe","year":"2022","unstructured":"Agashe RP, Lippman SM, Kurzrock R (2022) JAK: Not just another kinase. Mol Cancer Ther 21(12):1757\u20131764","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"5542_CR3","doi-asserted-by":"publisher","first-page":"F814","DOI":"10.1152\/ajprenal.00507.2020","volume":"320","author":"R Ali","year":"2021","unstructured":"Ali R, Patel S, Hussain T (2021) Angiotensin type 2 receptor activation limits kidney injury during the early phase and induces Treg cells during the late phase of renal ischemia. Am J Physiol Renal Physiol 320(5):F814\u2013F825","journal-title":"Am J Physiol Renal Physiol"},{"issue":"3","key":"5542_CR4","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.pcad.2016.10.002","volume":"59","author":"C Bavishi","year":"2016","unstructured":"Bavishi C, Bangalore S, Messerli FH (2016) Renin angiotensin aldosterone system inhibitors in hypertension: Is there evidence for benefit independent of blood pressure reduction? Prog Cardiovasc Dis 59(3):253\u2013261","journal-title":"Prog Cardiovasc Dis"},{"issue":"21","key":"5542_CR5","doi-asserted-by":"publisher","first-page":"3336","DOI":"10.3390\/cells11213336","volume":"11","author":"SK Bhullar","year":"2022","unstructured":"Bhullar SK, Dhalla NS (2022) Angiotensin II-induced signal transduction mechanisms for cardiac hypertrophy. Cells 11(21):3336","journal-title":"Cells"},{"issue":"5","key":"5542_CR6","first-page":"617","volume":"49","author":"SL Bourque","year":"2010","unstructured":"Bourque SL, Adams MA, Nakatsu K, Winterborn A (2010) Comparison of buprenorphine and meloxicam for postsurgical analgesia in rats: Effects on body weight, locomotor activity, and hemodynamic parameters. Journa of the American Association for Laboratory Animal Science: JAALAS 49(5):617","journal-title":"Journa of the American Association for Laboratory Animal Science: JAALAS"},{"issue":"1_suppl","key":"5542_CR7","doi-asserted-by":"publisher","first-page":"S84","DOI":"10.1177\/14703203010020011501","volume":"2","author":"D Casellas","year":"2001","unstructured":"Casellas D, Herizi A, Artuso A, Mimran A, Jover B (2001) Candesartan prevents L-NAME-induced cardio-renal injury in spontaneously hypertensive rats beyond hypotensive effects. J Renin Angiotensin Aldosterone Syst 2(1_suppl):S84\u2013S90","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"issue":"5","key":"5542_CR8","doi-asserted-by":"publisher","DOI":"10.31083\/j.rcm2305165","volume":"23","author":"A Caturano","year":"2022","unstructured":"Caturano A, Vetrano E, Galiero R, Salvatore T, Docimo G, Epifani R, Alfano M, Sardu C, Marfella R, Rinaldi L, Sasso FC (2022) Cardiac hypertrophy: From pathophysiological mechanisms to heart failure development. Rev Cardiovasc Med 23(5):165","journal-title":"Rev Cardiovasc Med"},{"issue":"2","key":"5542_CR9","doi-asserted-by":"publisher","first-page":"146","DOI":"10.7861\/clinmed.2019-0422","volume":"20","author":"RS Chahal","year":"2020","unstructured":"Chahal RS, Chukwu CA, Kalra PR, Kalra PA (2020) Heart failure and acute renal dysfunction in the cardiorenal syndrome. Clin Med 20(2):146\u2013150","journal-title":"Clin Med"},{"issue":"9","key":"5542_CR10","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1038\/ki.2008.380","volume":"74","author":"S Chen","year":"2008","unstructured":"Chen S, Ge Y, Si J, Rifai A, Dworkin LD, Gong R (2008) Candesartan suppresses chronic renal inflammation by a novel antioxidant action independent of AT1R blockade. Kidney Int 74(9):1128\u20131138","journal-title":"Kidney Int"},{"issue":"9","key":"5542_CR11","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s11906-023-01248-2","volume":"25","author":"S Cutrell","year":"2023","unstructured":"Cutrell S, Alhomoud IS, Mehta A, Talasaz AH, Van Tassell B, Dixon DL (2023) ACE-inhibitors in hypertension: A historical perspective and current insights. Curr Hypertens Rep 25(9):243\u2013250","journal-title":"Curr Hypertens Rep"},{"issue":"Supplement_1","key":"5542_CR12","volume":"11","author":"A Demikhov","year":"2022","unstructured":"Demikhov A, Demikhova N, Orlovskiy A, Zharkova A (2022) Heart failure correction in patients with chronic renocardiac syndrome. Eur Heart J Acute Cardiovasc Care 11(Supplement_1):zuac041-004","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"issue":"8","key":"5542_CR13","doi-asserted-by":"publisher","DOI":"10.1111\/jfbc.12952","volume":"43","author":"RA Eid","year":"2019","unstructured":"Eid RA, Alkhateeb MA, El\u2010Kott AF, Eleawa SM, Zaki MSA, Alaboodi SA, Salem Al\u2010Shudiefat AA-R, Aldera H, Alnamar NM, Alassiri M, Khalil MA (2019) A high\u2010fat diet rich in corn oil induces cardiac fibrosis in rats by activating JAK2\/STAT3 and subsequent activation of ANG II\/TGF\u20101\u03b2\/Smad3 pathway: the role of ROS and IL\u20106 trans\u2010signaling. J Food Biochem 43(8):e12952","journal-title":"J Food Biochem"},{"issue":"7","key":"5542_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27072048","volume":"27","author":"G El-Arif","year":"2022","unstructured":"El-Arif G, Khazaal S, Farhat A, Harb J, Annweiler C, Wu Y, Cao Z, Kovacic H, Abi Khattar Z, Fajloun Z, Sabatier JM (2022) Angiotensin II type I receptor (AT1R): the gate towards COVID-19-associated diseases. Molecules 27(7):2048","journal-title":"Molecules"},{"issue":"11","key":"5542_CR15","doi-asserted-by":"publisher","first-page":"347","DOI":"10.3390\/ph13110347","volume":"13","author":"S Hamid","year":"2020","unstructured":"Hamid S, Rhaleb IA, Kassem KM, Rhaleb NE (2020) Role of kinins in hypertension and heart failure. Pharmaceuticals 13(11):347","journal-title":"Pharmaceuticals"},{"issue":"1","key":"5542_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-58393-w","volume":"10","author":"M Hamzaoui","year":"2020","unstructured":"Hamzaoui M, Djerada Z, Brunel V, Mulder P, Richard V, Bellien J, Guerrot D (2020) 5\/6 nephrectomy induces different renal, cardiac and vascular consequences in 129\/Sv and C57BL\/6JRj mice. Sci Rep 10(1):1524","journal-title":"Sci Rep"},{"key":"5542_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116556","volume":"174","author":"J He","year":"2024","unstructured":"He J, He Z, Wang H, Zhang C, Pei T, Yan S, Yan Y, Wang F, Chen Y, Yuan N, Wang M, Xiao W (2024) Caffeic acid alleviates skeletal muscle atrophy in 5\/6 nephrectomy rats through the TLR4\/MYD88\/NF-kB pathway. Biomed Pharmacother 174:116556","journal-title":"Biomed Pharmacother"},{"key":"5542_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1023177","volume":"12","author":"B Huang","year":"2022","unstructured":"Huang B, Lang X, Li X (2022) The role of IL-6\/JAK2\/STAT3 signaling pathway in cancers. Front Oncol 12:1023177","journal-title":"Front Oncol"},{"key":"5542_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1336102","volume":"15","author":"H Jiang","year":"2024","unstructured":"Jiang H, Yang J, Li T, Wang X, Fan Z, Ye Q, Du Y (2024) JAK\/STAT3 signaling in cardiac fibrosis: a promising therapeutic target. Front Pharmacol 15:1336102","journal-title":"Front Pharmacol"},{"key":"5542_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s40697-015-0075-4","volume":"2","author":"JG Kingma Jr","year":"2015","unstructured":"Kingma JG Jr, Simard D, Rouleau JR (2015) Renocardiac syndromes: physiopathology and treatment stratagems. Can J Kidney Health Dis 2:75","journal-title":"Can J Kidney Health Dis"},{"key":"5542_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1233259","volume":"11","author":"Y Liu","year":"2023","unstructured":"Liu Y, Wang W, Zhang J, Gao S, Xu T, Yin Y (2023) JAK\/STAT signaling in diabetic kidney disease. Front Cell Dev Biol 11:1233259","journal-title":"Front Cell Dev Biol"},{"issue":"4","key":"5542_CR22","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2\u2212 \u0394\u0394CT method. Methods 25(4):402\u2013408","journal-title":"Methods"},{"issue":"4","key":"5542_CR23","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3892\/etm.2023.11852","volume":"25","author":"MA Maranduca","year":"2023","unstructured":"Maranduca MA, Clim A, Pinzariu AC, Statescu C, Sascau RA, Tanase DM, Serban IL (2023) Role of arterial hypertension and angiotensin II in chronic kidney disease. Exp Ther Med 25(4):153","journal-title":"Exp Ther Med"},{"issue":"11","key":"5542_CR24","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41581-022-00616-6","volume":"18","author":"K Matsushita","year":"2022","unstructured":"Matsushita K, Ballew SH, Wang AYM, Kalyesubula R, Schaeffner E, Agarwal R (2022) Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease. Nat Rev Nephrol 18(11):696\u2013707","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"5542_CR25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s42399-022-01347-2","volume":"5","author":"A Minciunescu","year":"2022","unstructured":"Minciunescu A, Genovese L, deFilippi C (2022) Cardiovascular alterations and structural changes in the setting of chronic kidney disease: a review of cardiorenal syndrome type 4. SN Compr Clin Med 5(1):15","journal-title":"SN Compr Clin Med"},{"issue":"7274","key":"5542_CR26","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1136\/bmj.321.7274.1440","volume":"321","author":"CE Mogensen","year":"2000","unstructured":"Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, Cooper ME (2000) Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 321(7274):1440\u20131444","journal-title":"BMJ"},{"issue":"10","key":"5542_CR27","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1007\/s00210-021-02130-1","volume":"394","author":"RM Mohamed","year":"2021","unstructured":"Mohamed RM, Elshazly SM, Nafea OE, Abd El Motteleb DM (2021) Comparative cardioprotective effects of carvedilol versus atenolol in a rat model of cardiorenal syndrome type 4. Naunyn-Schmiedeberg\u2019s Arch Pharmacol 394(10):2117\u20132128","journal-title":"Naunyn-Schmiedeberg's Arch Pharmacol"},{"key":"5542_CR28","doi-asserted-by":"publisher","DOI":"10.1590\/s2175-97902022e20978","volume":"58","author":"RMSM Mohamed","year":"2022","unstructured":"Mohamed RMSM, Elshazly SM, Mahmoud NM (2022) Amlexanox exhibits cardioprotective effects in 5\/6 nephrectomized rats. Braz J Pharm Sci 58:e20978","journal-title":"Braz J Pharm Sci"},{"issue":"5","key":"5542_CR29","doi-asserted-by":"publisher","first-page":"F553","DOI":"10.1152\/ajprenal.00595.2020","volume":"322","author":"JY Park","year":"2022","unstructured":"Park JY, Yoo KD, Bae E, Kim KH, Lee JW, Shin SJ, Lee JS, Kim YS, Yang SH (2022) Blockade of STAT3 signaling alleviates the progression of acute kidney injury to chronic kidney disease through antiapoptosis. Am J Physiol Renal Physiol 322(5):F553\u2013F572","journal-title":"Am J Physiol Renal Physiol"},{"issue":"12","key":"5542_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/antiox9121279","volume":"9","author":"E Ramos-Tovar","year":"2020","unstructured":"Ramos-Tovar E, Muriel P (2020) Molecular mechanisms that link oxidative stress, inflammation, and fibrosis in the liver. Antioxidants Basel 9(12):1279","journal-title":"Antioxidants Basel"},{"issue":"16","key":"5542_CR31","doi-asserted-by":"publisher","first-page":"e840","DOI":"10.1161\/CIR.0000000000000664","volume":"139","author":"J Rangaswami","year":"2019","unstructured":"Rangaswami J, Bhalla V, Blair JE, Chang TI, Costa S, Lentine KL, Blair JEA, Lerma EV, Mezue K, Molitch M, Mullens W, Ronco C, Tang WHW, McCullough PA, American Heart Association Council on the Kidney in Cardiovascular Disease and Council on Clinical Cardiology (2019) Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation 139(16):e840\u2013e878","journal-title":"Circulation"},{"issue":"10","key":"5542_CR32","volume":"14","author":"FR Rashid","year":"2022","unstructured":"Rashid FR, Abubakar M, Fayyaz H, Umer N, Shafiq A, Sajjad W, Ellahi A (2022) Renal effects of high-dose versus low-dose lisinopril in patients with diabetic nephropathy. Cureus 14(10):e29873","journal-title":"Cureus"},{"issue":"5","key":"5542_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/cells11050867","volume":"11","author":"A Rocca","year":"2022","unstructured":"Rocca A, Heeswijk RBV, Richiardi J, Meyer P, Hullin R (2022) The cardiomyocyte in heart failure with preserved ejection fraction\u2014victim of its environment? Cells 11(5):867","journal-title":"Cells"},{"issue":"1","key":"5542_CR34","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41572-024-00589-9","volume":"11","author":"P Romagnani","year":"2025","unstructured":"Romagnani P, Agarwal R, Chan JC, Levin A, Kalyesubula R, Karam S, Chan JCN, Nangaku M, Rodr\u00edguez-Iturbe B, Anders HJ (2025) Chronic kidney disease. Nat Rev Dis Primers 11(1):8","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"5542_CR35","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1053\/j.ackd.2018.08.004","volume":"25","author":"C Ronco","year":"2018","unstructured":"Ronco C, Bellasi A, Di Lullo L (2018) Cardiorenal syndrome: an overview. Adv Chronic Kidney Dis 25(5):382\u2013390","journal-title":"Adv Chronic Kidney Dis"},{"issue":"11","key":"5542_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24119422","volume":"24","author":"E Russo","year":"2023","unstructured":"Russo E, Bussalino E, Macci\u00f2 L, Verzola D, Saio M, Esposito P, Leoncini G, Pontremoli R, Viazzi F (2023) Non-haemodynamic mechanisms underlying hypertension-associated damage in target kidney components. Int J Mol Sci 24(11):9422","journal-title":"Int J Mol Sci"},{"issue":"4","key":"5542_CR37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0152554","volume":"11","author":"IM Sabler","year":"2016","unstructured":"Sabler IM, Berkovitch M, Sandbank J, Kozer E, Dagan Z, Goldman M, Bahat H, Stav K, Zisman A, Klin B, Abu-Kishk I (2016) Exposure to hyperbaric oxygen intensified vancomycin-induced nephrotoxicity in rats. PLoS ONE 11(4):e0152554","journal-title":"PLoS ONE"},{"issue":"6","key":"5542_CR38","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/hr.2009.44","volume":"32","author":"T Saruta","year":"2009","unstructured":"Saruta T, Hayashi K, Ogihara T, Nakao K, Fukui T, Fukiyama K (2009) Effects of candesartan and amlodipine on cardiovascular events in hypertensive patients with chronic kidney disease: subanalysis of the CASE-J study. Hypertens Res 32(6):505\u2013512","journal-title":"Hypertens Res"},{"issue":"3","key":"5542_CR39","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1177\/0192623318761348","volume":"46","author":"KA Schafer","year":"2018","unstructured":"Schafer KA, Eighmy J, Fikes JD, Halpern WG, Hukkanen RR, Long GG, Meseck EK, Patrick DJ, Thibodeau MS, Wood CE, Francke S (2018) Use of severity grades to characterize histopathologic changes. Toxicol Pathol 46(3):256\u2013265","journal-title":"Toxicol Pathol"},{"issue":"1","key":"5542_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-00977-0","volume":"14","author":"G Semenzato","year":"2024","unstructured":"Semenzato G, Calabretto G, Teramo A, Gasparini VR, Rampazzo E, Baril\u00e0 G, Zambello R (2024) The constitutive activation of STAT3 gene and its mutations are at the crossroad between LGL leukemia and autoimmune disorders. Blood Cancer J 14(1):13","journal-title":"Blood Cancer J"},{"issue":"3","key":"5542_CR41","doi-asserted-by":"publisher","first-page":"242","DOI":"10.30802\/AALAS-JAALAS-19-000084","volume":"59","author":"NH Shomer","year":"2020","unstructured":"Shomer NH, Allen-Worthington KH, Hickman DL, Jonnalagadda M, Newsome JT, Slate AR, Valentine H, Williams AM, Wilkinson M (2020) Review of rodent euthanasia methods. J Am Assoc Lab Anim Sci 59(3):242\u2013253","journal-title":"J Am Assoc Lab Anim Sci"},{"issue":"1","key":"5542_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-74003-5","volume":"14","author":"MS Soh","year":"2024","unstructured":"Soh MS, Won KH, Kim JJ, Lee SY, Hyon MS, Youn HJ, Won K, Rha S-W, Kim D-I, Ahn Y, Kim BJ, Choi D-J, Park J-S, Kim D-K, Park W-J, Lim H-S, Tahk SJ (2024) Phase III randomized clinical trial of efficacy and safety of amlodipine and candesartan cilexetil combination for hypertension treatment. Sci Rep 14(1):22940","journal-title":"Sci Rep"},{"key":"5542_CR43","doi-asserted-by":"publisher","DOI":"10.33549\/physiolres.932003","author":"J \u0160v\u00edglerov\u00e1","year":"2010","unstructured":"\u0160v\u00edglerov\u00e1 J, Kuncova J, Nalos L, Tonar Z, Rajdl D, \u0160tengl M (2010) Cardiovascular parameters in rat model of chronic renal failure induced by subtotal nephrectomy. Physiol Res, 59.","journal-title":"Physiol Res"},{"key":"5542_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115166","volume":"165","author":"JT Yu","year":"2023","unstructured":"Yu JT, Fan S, Li XY, Hou R, Hu XW, Wang JN, Shan RR, Dong ZH, Xie MM, Dong YH, Shen XY, Jin J, Wen JG, Liu MM, Wang W, Meng XM (2023) Novel insights into STAT3 in renal diseases. Biomed Pharmacother 165:115166","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"5542_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01036-5","volume":"7","author":"Q Yuan","year":"2022","unstructured":"Yuan Q, Tang B, Zhang C (2022) Signaling pathways of chronic kidney diseases, implications for therapeutics. Signal Transduct Target Ther 7(1):182","journal-title":"Signal Transduct Target Ther"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05542-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05542-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05542-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:06:15Z","timestamp":1787670375000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05542-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":45,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["5542"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05542-z","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,9]]},"assertion":[{"value":"3 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All experimental procedures were conducted in accordance with the ARRIVE 2.0 guidelines. The protocol was approved by The Institutional Animal Care and Use Committee Zagazig University (ZU-IACUC) \"No. ZU-IACUC\/3\/F\/2\/2020\" and it is consistent with the National Institutes of Health guides for care and use of laboratory animals (NIH publications) \"No.8023, revised 1996\".","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare consent of participation.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors give consent for the publication of this study.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}